End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia
Journal of Clinical Oncology · 2025-02 · 43 (4) · 381-391
DOI: 10.1200/jco.24.01192 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Clinical Oncology, 2025-02. Verfasst von Florian Simon und 32 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldor…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Surrogate end points are commonly used to estimate treatment efficacy in clinical studies of chronic lymphocytic leukemia (CLL). This patient- and trial-level analysis describes the correlation between progression-free survival (PFS) and minimal residual disease (MRD) with overall survival (OS) in first-line trials for CLL. PATIENTS AND METHODS First, patient-level correlation was confirmed using source data from 12 frontline German CLL Study Group (GCLLSG)-trials. Additionally, a joint-frailty copula model was fitted to validate correlation in the setting of targeted therapies (TT). Second, a meta-analysis of first-line phase III trials in CLL from 2008 to 2024 was performed. Treatment effect correlation was quantified from seven GCLLSG and nine published trials, using hazard ratios (HRs) for time-to-event and odds ratios for binary end points. RESULTS The GCLLSG analysis set comprised 4,237 patients. Patient-level correlation for PFS/OS was strong with Spearman Rho >0.9. The joint-frailty copula indicated a weak correlation for chemotherapy/chemoimmunotherapy (C/CIT) with a tau of 0.52 (95% CI, 0.49 to 0.55) while the correlation was strong for TT (tau, 0.91 [95% CI, 0.89 to 0.93). The meta-analysis set contained a total of 8,065 patients including 5,198 (64%) patients treated with C/CIT and 2,867 (36%) treated with TT. Treatment-effect correlation of the HRs for PFS and OS was R = 0.75 (95% CI, 0.74 to 0.76, R 2 = 0.56) while correlation of end-of-treatment MRD with PFS and OS was R = 0.88 (95% CI, –0.87 to 0.89; R 2 = 0.78) and 0.71 (95% CI, 0.69 to 0.73; R 2 = 0.5), respectively. CONCLUSION Patient-level correlation was confirmed in the setting of TTs while treatment-effect correlation between PFS and OS remains uncertain. MRD response status showed a high treatment-effect correlation with PFS but not OS, with the caveat of a limited number of randomized trials with available MRD data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.
- St Marienhospital Cologne, Oncogeriatric Unit, Department of Geriatric Medicine, Cologne, Germany.
- Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
- Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany.
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
ORCID-Profile: Florian Simon, Rudy Ligtvoet, Paula Cramer, Nadine Kutsch, Moritz Fürstenau, Petra Langerbeins, Anna-Maria Fink, Eugen Tausch, Martin Dreyling, Lothar Müller, Werner J Heinz, Sebastian Böttcher, Peter Dreger, Philipp B Staber, Carsten U Niemann, Arnon P Kater, Michael Hallek, Othman Al-Sawaf
Zitieren
APA
Simon, F., Ligtvoet, R., Robrecht, S., Cramer, P., Kutsch, N., Fürstenau, M., Goede, V., von Tresckow, J., Langerbeins, P., Fink, A. M., Huber, H., Tausch, E., Schneider, C., Wendtner, C. M., Ritgen, M., Dreyling, M., Müller, L., Jacobasch, L., Heinz, W. J., …, & Al-Sawaf, O. (2025). End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 43(4), 381-391. https://doi.org/10.1200/jco.24.01192
Vancouver
Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, et al. End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 2025;43(4):381-391. doi:10.1200/jco.24.01192
BibTeX
@article{Simon2025,
author = {Simon, Florian and Ligtvoet, Rudy and Robrecht, Sandra and Cramer, Paula and Kutsch, Nadine and Fürstenau, Moritz and Goede, Valentin and von Tresckow, Julia and Langerbeins, Petra and Fink, Anna-Maria and Huber, Henriette and Tausch, Eugen and Schneider, Christof and Wendtner, Clemens M and Ritgen, Matthias and Dreyling, Martin and Müller, Lothar and Jacobasch, Lutz and Heinz, Werner J and Vehling-Kaiser, Ursula and Sivcheva, Liliya and Böttcher, Sebastian and Dreger, Peter and Illmer, Thomas and Gregor, Michael and Staber, Philipp B and Stilgenbauer, Stephan and Niemann, Carsten U and Kater, Arnon P and Fischer, Kirsten and Eichhorst, Barbara and Hallek, Michael and Al-Sawaf, Othman},
title = {End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {4},
pages = {381--391},
doi = {10.1200/jco.24.01192}
}
EUVIMED